- Visibility0
- Citations0
- Sentiment50
- Site quality80
- AI readiness29
AI assistants do not name BridgeBio in any of their 60 answers. Its overall score is 26 out of 100, ranking 1,693rd of 2,047 companies studied. The website passes 4 out of 14 technical checks, showing some readiness for AI tools.
We asked 15 unbranded questions about the healthcare market: none named BridgeBio. AI assistants named it in none of 60 answers. The typical healthcare company is named in 3.3% of answers. By how often it is named, BridgeBio ranks 69 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
The company is not named in this answer
“What are the most promising new therapies for rare genetic diseases in the US?”
Gene therapies are rapidly emerging as some of the most promising new treatments for rare genetic diseases in the US, with several recent FDA approvals and many more in clinical trials. These therapies aim to address the root cause of diseases by correcting or replacing defective genes.
Here are some notable recent advancements and promising therapies:
Newly Approved Gene Therapies:
Fayuvi (rebisufligene etisparvovec-hopf): Approved in September 2026, Fayuvi is the first FDA-approved gene therapy for Sanfilippo syndrome type A (MPS IIIA), a fatal neurodegenerative disease affecti …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtPassed
An llms.txt that tells language models what the site offers.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 36 of 100 · 97% of checks could run · checked on October 5, 2026 · bridgebio.com · 2,047 companies scanned
4 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Passedllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotallowed
- ClaudeBotallowed
- Anthropic-AIallowed
- Google-Extendedallowed
- Applebot-Extendedallowed
- Meta-ExternalAgentallowed
- FacebookBotallowed
- Bytespiderallowed
- CCBotallowed
- Diffbotallowed
- Omgilibotallowed
- OAI-SearchBotallowed
- Claude-SearchBotallowed
- PerplexityBotallowed
- Applebotallowed
- Amazonbotallowed
- YouBotallowed
- ChatGPT-Userallowed
- Claude-Userallowed
- Perplexity-Userallowed
- DuckAssistBotallowed
- MistralAI-Userallowed
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as US-listed.
- Alternatives to gene therapy for managing chronic rare diseases
- How to find support resources for patients undergoing treatment for a genetically driven cancer?
- What factors affect the cost of genetic disease treatments in the United States?
- What are common real-world applications for therapies targeting limb-girdle muscular dystrophy?
- Are investigational medicines for rare genetic conditions worth considering before FDA approval?
- Targeted oncology therapies compared to traditional chemotherapy—what's the difference?
- Best options for patients with genetically driven cancers seeking innovative treatments
- Gene therapy vs small molecule drugs for treating inherited disorders—how do they compare?
- How are advanced therapies being used to treat transthyretin amyloidosis in the US?
- New trends in clinical development for orphan drugs targeting rare conditions
- Is enrolling in a clinical trial for a novel genetic disease therapy a good option for patients?
- What steps should you take if you experience side effects from a newly approved genetic therapy?
- How do insurance plans typically cover novel oncology therapies with genetic targets?
- What are the most promising new therapies for rare genetic diseases in the US?
- What non-genetic treatment options exist for inherited metabolic disorders?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.